Business Context and Reporting Period
Company: Abbott Laboratories
Filing Type: Form 8-K (Current Report)
Date of Report: June 23, 2005
Subject: Regulation FD Disclosure regarding the Xinlay Expanded Access Program.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The report focuses exclusively on a regulatory development concerning an investigational drug.
Material Changes
Regulatory Approval: Abbott Laboratories received permission from the U.S. Food and Drug Administration (FDA) to initiate an expanded access program for Xinlay (atrasentan).
Target Population: The program is for eligible men with late-stage, hormone-refractory prostate cancer in the U.S.
Timeline: The program is scheduled to begin later in the summer of 2005.
Drug Status: A New Drug Application (NDA) for Xinlay is currently under FDA review based on Phase II and III clinical trials.
Outlook, Risks, and Management Commentary
- Drug Mechanism: Xinlay is an investigational, oral, once-daily, non-hormonal, non-chemotherapy agent classified as a selective endothelin-A receptor antagonist (SERA). It targets endothelin-1, a protein involved in cancer cell spread.
- Clinical Context: The NDA submission includes data on disease progression and delay in the onset of bone pain. Prostate cancer is the second most common cancer in American men and the second leading cause of cancer death.
- Expanded Access Purpose: These programs provide investigational agents to patients with serious diseases where no satisfactory alternative therapy exists.
- Legal Disclaimer: The information is furnished, not filed, under Regulation FD. It is not intended to constitute a determination that the information is material or complete for investment decisions.
Investor Verification Checklist
- Verify the specific eligibility criteria for the Xinlay expanded access program.
- Monitor the FDA's review timeline and potential approval date for the Xinlay NDA.
- Review ongoing clinical trial results for Xinlay in non-metastatic and hormone-naive prostate cancer patients.
- Assess the competitive landscape for non-hormonal treatments for hormone-refractory prostate cancer.